Factorial study of the effect of n-3 fatty acid supplementation and atorvastatin on the kinetics of HDL apolipoproteins A-I and A-II in men with abdominal obesity
- PMID: 16825679
- DOI: 10.1093/ajcn/84.1.37
Factorial study of the effect of n-3 fatty acid supplementation and atorvastatin on the kinetics of HDL apolipoproteins A-I and A-II in men with abdominal obesity
Abstract
Background: Disturbed HDL metabolism in insulin-resistant, obese subjects may account for an increased risk of cardiovascular disease. Fish oils and atorvastatin increase plasma HDL cholesterol, but the underlying mechanisms responsible for this change are not fully understood.
Objective: We studied the independent and combined effects of fish oils and atorvastatin on the metabolism of HDL apolipoprotein A-I (apo A-I) and HDL apo A-II in obese men.
Design: We conducted a 6-wk randomized, placebo-controlled, 2 x 2 factorial intervention study of the effects of fish oils (4 g/d) and atorvastatin (40 mg/d) on the kinetics of HDL apo A-I and HDL apo A-II in 48 obese men with dyslipidemia with intravenous administration of [d3]-leucine. Isotopic enrichments of apo A-I and apo A-II were measured with gas chromatography-mass spectrometry with kinetic parameters derived from a multicompartmental model (SAAM II).
Results: Fish oils and atorvastatin significantly decreased plasma triacylglycerols and increased HDL cholesterol and HDL2 cholesterol (P < 0.05 for main effects). A significant (P < 0.02) main effect of fish oils was observed in decreasing the fractional catabolic rate of HDL apo A-I and HDL apo A-II. This was coupled with a significant decrease in the corresponding production rates, accounting for a lack of treatment effect on plasma concentrations of apo A-I and apo A-II. Atorvastatin did not significantly alter the concentrations or kinetic parameters of HDL apo A-I and HDL apo A-II. None of the treatments altered insulin resistance.
Conclusions: Fish oils, but not atorvastatin, influence HDL metabolism chiefly by decreasing both the catabolism and production of HDL apo A-I and HDL apo A-II in insulin-resistant obese men. Addition of atorvastatin to treatment with fish oils had no additional effect on HDL kinetics compared with fish oils alone.
Similar articles
-
Effects of atorvastatin and n-3 fatty acid supplementation on VLDL apolipoprotein C-III kinetics in men with abdominal obesity.Am J Clin Nutr. 2010 Apr;91(4):900-6. doi: 10.3945/ajcn.2009.28422. Epub 2010 Feb 24. Am J Clin Nutr. 2010. PMID: 20181806 Clinical Trial.
-
Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia.Diabetes. 2002 Aug;51(8):2377-86. doi: 10.2337/diabetes.51.8.2377. Diabetes. 2002. PMID: 12145148 Clinical Trial.
-
Randomized controlled trial of the effect of n-3 fatty acid supplementation on the metabolism of apolipoprotein B-100 and chylomicron remnants in men with visceral obesity.Am J Clin Nutr. 2003 Feb;77(2):300-7. doi: 10.1093/ajcn/77.2.300. Am J Clin Nutr. 2003. PMID: 12540386 Clinical Trial.
-
N-3 fatty acids from fish oil. Effects on plasma lipoproteins and hypertriglyceridemic patients.Ann N Y Acad Sci. 1993 Jun 14;683:16-34. doi: 10.1111/j.1749-6632.1993.tb35689.x. Ann N Y Acad Sci. 1993. PMID: 8352438 Review.
-
Thematic review series: patient-oriented research. What have we learned about HDL metabolism from kinetics studies in humans?J Lipid Res. 2006 Aug;47(8):1631-42. doi: 10.1194/jlr.R600008-JLR200. Epub 2006 May 9. J Lipid Res. 2006. PMID: 16685079 Review.
Cited by
-
Dietary Omega-6/Omega-3 Polyunsaturated Fatty Acid (PUFA) and Omega-3 Are Associated With General and Abdominal Obesity in Adults: UK National Diet and Nutritional Survey.Cureus. 2022 Oct 12;14(10):e30209. doi: 10.7759/cureus.30209. eCollection 2022 Oct. Cureus. 2022. PMID: 36381926 Free PMC article.
-
Effects of prescription omega-3-acid ethyl esters on non--high-density lipoprotein cholesterol when coadministered with escalating doses of atorvastatin.Mayo Clin Proc. 2010 Feb;85(2):122-8. doi: 10.4065/mcp.2009.0397. Mayo Clin Proc. 2010. PMID: 20118387 Free PMC article. Clinical Trial.
-
Nutrient patterns and risk of cataract: a case-control study.Int J Ophthalmol. 2017 Apr 18;10(4):586-592. doi: 10.18240/ijo.2017.04.14. eCollection 2017. Int J Ophthalmol. 2017. PMID: 28503432 Free PMC article.
-
Dose-dependent regulation of high-density lipoprotein metabolism with rosuvastatin in the metabolic syndrome.J Clin Endocrinol Metab. 2008 Feb;93(2):430-7. doi: 10.1210/jc.2007-0854. Epub 2007 Nov 20. J Clin Endocrinol Metab. 2008. PMID: 18029469 Free PMC article. Clinical Trial.
-
The Impact of OMEGA-3 Fatty Acids Supplementation on Insulin Resistance and Content of Adipocytokines and Biologically Active Lipids in Adipose Tissue of High-Fat Diet Fed Rats.Nutrients. 2019 Apr 12;11(4):835. doi: 10.3390/nu11040835. Nutrients. 2019. PMID: 31013835 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical